News | January 21, 2008

CE Granted for Boston Scientific’s New Defribrillator, ICD

January 22, 2008 - Boston Scientific Corp. today announced CE Mark approval for its COGNIS cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN implantable cardioverter defibrillator (ICD), representing entirely new platforms to treat heart failure and sudden cardiac death.

The high-energy devices are extrmely small and thin at 32.5 cc and 31.5 cc respectively, while less than 10 mm thick. Both devices offer extended battery longevity, self-correcting software and improved programming technology. Both devices also offer SafetyCore, a feature that in the unlikely event of a system error provides lifesaving shock therapy and basic pacing functionality.

Key features of the COGNIS CRT-D include the SmartDelay, which is designed to propose programmable device settings to enable physicians to tailor individualized pacing therapy for their patients. Bi-V Trigger is engineered for physicians to manage heart failure patients with frequent atrial arrhythmias. The electronic repositioning feature provides physicians with six configurations for stimulating the left side of the heart even after implant, which may help avoid an additional surgical procedure.

The TELIGEN ICD is a thin device designed with patient comfort in mind. Reverse Mode Switch is designed to eliminate unnecessary ventricular pacing. Quick Convert provides the ability for patients to receive pacing therapy for ventricular tachycardias.

The COGNIS CRT-D and the TELIGEN ICD are pending approval by the FDA and are not available for sale in the United States.

For more information: www.bostonscientific.com

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init